Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Sep-13 7:21 PM View:  | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 3,230 | -- | -- | (2%) 170.09K to 166.86K | |
| 13-Sep-13 7:15 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 82,022 | -- | -- | (100%) 82.02K to 0 | |
| 13-Sep-13 7:19 PM View: | O'Leary Brendan Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 21,302 | -- | -- | (100%) 21.3K to 0 | |
| 13-Sep-13 7:21 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 166,860 | -- | -- | (100%) 166.86K to 0 | |
| 13-Sep-13 7:21 PM View: | Eastham Karin Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 6,000 | -- | -- | (33%) 18.11K to 12.11K | |
| 13-Sep-13 7:17 PM View: | Truex Paul F Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 11,270 | -- | -- | (100%) 11.27K to 0 | |
| 13-Sep-13 7:19 PM View: | Schmid John P. Chief Financial Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 107,639 | -- | -- | (100%) 107.64K to 0 | |
| 13-Sep-13 7:07 PM View: | Kabakoff David S Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 111,366 | -- | -- | (100%) 111.37K to 0 | |
| 13-Sep-13 7:12 PM View: | Stein Jeffrey President & CEO Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 210,457 | -- | -- | (100%) 210.46K to 0 | |
| 13-Sep-13 6:19 PM View: | Thompson John Craig Chief Commercial Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 2,455 | -- | -- | (100%) 2.46K to 0 | |
| 13-Sep-13 7:21 PM View: | Eastham Karin Director | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 12,114 | -- | -- | (100%) 12.11K to 0 | |
| 13-Sep-13 7:14 PM View: | Morneau Michael VP Finance & CAO | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 14,070 | -- | -- | (100%) 14.07K to 0 | |
| 13-Sep-13 7:17 PM View: | Bartizal Ken Chief Development Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 96,400 | -- | -- | (100%) 96.4K to 0 | |
| 13-Sep-13 7:15 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 11-Sep-13 | Disposition | 12,190 | -- | -- | (13%) 94.21K to 82.02K | |
| 23-Jul-13 5:10 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 22-Jul-13 | Market Sale (Planned) | 1,000 | $12.10 | $12,100.00 | (< 1%) 170.01K to 169.01K | (13%) |
| 16-Jul-13 6:09 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 15-Jul-13 | Market Sale (Planned) | 3,500 | $10.55 | $36,925.00 | (2%) 173.51K to 170.01K | (30%) |
| 12-Jul-13 6:57 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 12-Jul-13 | Market Sale (Planned) | 5,000 | $10.10 | $50,500.00 | (3%) 178.51K to 173.51K | (35%) |
| 12-Jul-13 6:56 PM View: | Morneau Michael VP Finance & CAO | Trius Therapeutics Inc (TSRX) | 11-Jul-13 | Market Option Sale (Planned) | 20,000 | $9.75 | $195,000.00 | (61%) 32.55K to 12.54K | (40%) |
| 12-Jul-13 6:56 PM View: | Morneau Michael VP Finance & CAO | Trius Therapeutics Inc (TSRX) | 11-Jul-13 | Option Exercise | 20,000 | $4.00 | $80,000.00 | 159% 12.54K to 32.55K | |
| 12-Jul-13 6:57 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 11-Jul-13 | Market Sale (Planned) | 500 | $9.32 | $4,660.00 | (< 1%) 179.01K to 178.51K | (47%) |
| 12-Jul-13 6:57 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 10-Jul-13 | Market Sale (Planned) | 1,000 | $8.58 | $8,580.00 | (< 1%) 180.01K to 179.01K | (59%) |
| 01-Jul-13 4:44 PM View: | Bartizal Ken Chief Development Officer | Trius Therapeutics Inc (TSRX) | 01-Jul-13 | Market Sale (Planned) | 2,000 | $8.14 | $16,280.00 | (2%) 97.3K to 95.3K | (68%) |
| 01-Jul-13 4:43 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 01-Jul-13 | Market Sale (Planned) Duplicate | 2,000 | $8.14 | $16,280.00 | (2%) 94.89K to 92.89K | (68%) |
| 12-Jun-13 7:27 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 12-Jun-13 | Market Sale (Planned) | 3,000 | $9.08 | $27,249.90 | (2%) 183.01K to 180.01K | (50%) |
| 11-Jun-13 7:57 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 11-Jun-13 | Market Sale (Planned) | 1,000 | $8.94 | $8,940.00 | (< 1%) 184.01K to 183.01K | (53%) |
| 04-Jun-13 7:53 PM View: | Bartizal Ken Chief Development Officer | Trius Therapeutics Inc (TSRX) | 04-Jun-13 | Market Sale (Planned) | 2,000 | $7.90 | $15,800.00 | (2%) 99.3K to 97.3K | (73%) |
| 03-Jun-13 4:49 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 03-Jun-13 | Market Sale (Planned) | 2,000 | $7.75 | $15,500.00 | (2%) 96.89K to 94.89K | (76%) |
| 28-May-13 7:53 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 24-May-13 | Market Sale (Planned) Duplicate | 12,000 | $7.93 | $95,119.20 | (11%) 108.45K to 96.45K | (72%) |
| 28-May-13 7:55 PM View: | Bartizal Ken Chief Development Officer | Trius Therapeutics Inc (TSRX) | 24-May-13 | Market Sale (Planned) | 12,000 | $7.93 | $95,119.20 | (11%) 110.93K to 98.93K | (72%) |
| 16-May-13 2:41 PM View: | Morneau Michael VP Finance & CAO | Trius Therapeutics Inc (TSRX) | 14-May-13 | Option Exercise | 20,000 | $4.00 | $80,000.00 | 188% 10.63K to 30.64K | |
| 16-May-13 2:28 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 14-May-13 | Market Sale (Planned) | 5,000 | $8.10 | $40,512.00 | (3%) 186.86K to 181.86K | (69%) |
| 16-May-13 2:27 PM View: | Bartizal Ken Chief Development Officer | Trius Therapeutics Inc (TSRX) | 14-May-13 | Market Sale (Planned) | 12,000 | $7.85 | $94,200.00 | (11%) 110.93K to 98.93K | (74%) |
| 16-May-13 2:41 PM View: | Morneau Michael VP Finance & CAO | Trius Therapeutics Inc (TSRX) | 14-May-13 | Market Option Sale (Planned) | 20,000 | $7.75 | $155,000.00 | (65%) 30.64K to 10.63K | (76%) |
| 15-May-13 8:35 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 13-May-13 | Market Sale (Planned) | 12,000 | $7.65 | $91,800.00 | (11%) 108.45K to 96.45K | (79%) |
| 14-May-13 1:22 PM View: | Kpcb Pbd Founders Fund, LLC 10% Owner | Trius Therapeutics Inc (TSRX) | 10-May-13 | Disposition (other) | 4,050 | -- | -- | (29%) 14.14K to 10.1K | |
| 14-May-13 1:25 PM View: | Kpcb Pandemic & Bio Defense... 10% Owner | Trius Therapeutics Inc (TSRX) | 10-May-13 | Disposition (other) | 680,850 | -- | -- | (29%) 2.38M to 1.7M | |
| 13-May-13 5:58 PM View: | Stack Risa Director | Trius Therapeutics Inc (TSRX) | 10-May-13 | Acquisition (other) | 591 | -- | -- | 100% 0 to 0.59K | |
| 13-May-13 1:27 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 10-May-13 | Market Sale (Planned) | 3,000 | $7.47 | $22,425.00 | (2%) 189.86K to 186.86K | (83%) |
| 26-Apr-13 2:40 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 24-Apr-13 | Market Sale (Planned) | 500 | $7.10 | $3,550.00 | (< 1%) 192.14K to 191.64K | (93%) |
| 18-Mar-13 2:52 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 15-Mar-13 | Market Sale (Planned) | 1,500 | $7.10 | $10,650.00 | (< 1%) 193.64K to 192.14K | (93%) |
| 25-Jun-12 1:07 PM View: | Schmid John P. CFO and Secretary | Trius Therapeutics Inc (TSRX) | 22-Jun-12 | Market Sale (Planned) | 1,800 | $6.00 | $10,800.00 | (2%) 109.44K to 107.64K | (128%) |
| 29-Mar-12 11:37 AM View: | Eastham Karin Director | Trius Therapeutics Inc (TSRX) | 27-Mar-12 | Option Exercise | 6,000 | $3.50 | $21,000.00 | 50% 12.11K to 18.11K | |
| 28-Mar-12 3:50 PM View: | Stein Jeffrey President and CEO Director | Trius Therapeutics Inc (TSRX) | 27-Mar-12 | Option Exercise | 38,462 | $0.52 | $20,000.20 | 22% 172.0K to 210.46K | |
| 28-Mar-12 3:50 PM View: | Schmid John P. CFO and Secretary | Trius Therapeutics Inc (TSRX) | 27-Mar-12 | Option Exercise | 5,000 | $1.29 | $6,450.00 | 5% 104.44K to 109.44K | |
| 28-Mar-12 7:50 PM View: | O'Leary Brendan Director | Trius Therapeutics Inc (TSRX) | 26-Mar-12 | Option Exercise | 21,302 | $2.82 | $59,999.60 | 100% 0 to 21.3K | |
| 27-Mar-12 7:49 PM View: | Finn John Chief Scientific Officer | Trius Therapeutics Inc (TSRX) | 26-Mar-12 | Option Exercise | 20,000 | $0.52 | $10,400.00 | 12% 172.83K to 192.83K | |
| 27-Mar-12 7:50 PM View: | Powell Michael Director | Trius Therapeutics Inc (TSRX) | 26-Mar-12 | Option Exercise | 9,302 | $1.29 | $11,999.60 | 100% 0 to 9.3K | |
| 27-Mar-12 5:57 PM View: | Prokocimer Philippe Chief Medical Officer | Trius Therapeutics Inc (TSRX) | 23-Mar-12 | Option Exercise | 6,244 | $0.52 | $3,246.88 | 6% 101.28K to 107.52K | |
| 02-Mar-12 2:38 PM View: | Schmid John P. CFO and Secretary | Trius Therapeutics Inc (TSRX) | 01-Mar-12 | Market Sale (Planned) | 500 | $5.04 | $2,520.00 | (< 1%) 104.94K to 104.44K | (171%) |
| 06-Feb-12 1:23 PM View: | Schmid John P. CFO and Secretary | Trius Therapeutics Inc (TSRX) | 02-Feb-12 | Market Sale (Planned) | 500 | $5.63 | $2,815.00 | (< 1%) 105.44K to 104.94K | (143%) |
